PERLIER - search results

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

mongrel 750 herbicide

crop culture pty ltd - clopyralid present as the potassium salt - water soluble granules - clopyralid present as the potassium salt pyridine active 750.0 g/kg - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

csl normal immunoglobulin vf (human) 800mg/5ml injection vial

csl behring australia pty ltd - normal immunoglobulin, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine; human immunoglobulin a - normal immunoglobulin-vf is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. it may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. in susceptible contacts of hepatitis a, measles and poliomyelitis, normal immunoglobulin-vf may be of value in preventing or modifying the disease. in general, the earlier in the incubation period of these diseases normal immunoglobulin-vf is given, the greater its effectiveness. hepatitis a-routine passive protection is recommended in persons exposed less than one week previously for the following categories of individuals, household contacts of an index case, who have not already had hepatitis a or have no serological evidence of immunity to the virus. common source exposures. when a vehicle such as food or water is identified as a common source of infection for multiple hepatitis cases, administration of normal immunoglobulin-vf should be considered for all those exposed to the source. institutional contacts. staff in institutions where hepatitis is endemic. routine prophylaxis is not recommended for school, office, factory or hospital contacts. rubella, although normal immunoglobulin-vf can prevent or modify the clinical disease in susceptible rubella contacts if given within 72 hours of exposure, it does not prevent viraemia in such patients. it should, therefore, not be relied upon to prevent congenital malformations due to rubella if given to susceptible pregnant women during the first trimester. measles (morbilli), normal immunoglobulin-vf is indicated for protection against measles in persons exposed less than one week previously. it is recommended in children under six months of age whose mothers have not had the disease, in children between six months and three years of age who have not been actively immunised and in immunosuppressed contacts of the index case. poliomyelitis, normal immunoglobulin-vf is recommended for susceptible contacts who have not been immunised against poliomyelitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl normal immunoglobulin vf (human) 320mg/2ml injection vial

csl behring australia pty ltd - normal immunoglobulin, quantity: 320 mg - injection, solution - excipient ingredients: glycine; human immunoglobulin a - normal immunoglobulin-vf is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. it may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. in susceptible contacts of hepatitis a, measles and poliomyelitis, normal immunoglobulin-vf may be of value in preventing or modifying the disease. in general, the earlier in the incubation period of these diseases normal immunoglobulin-vf is given, the greater its effectiveness. hepatitis a-routine passive protection is recommended in persons exposed less than one week previously for the following categories of individuals, household contacts of an index case, who have not already had hepatitis a or have no serological evidence of immunity to the virus. common source exposures. when a vehicle such as food or water is identified as a common source of infection for multiple hepatitis cases, administration of normal immunoglobulin-vf should be considered for all those exposed to the source. institutional contacts. staff in institutions where hepatitis is endemic. routine prophylaxis is not recommended for school, office, factory or hospital contacts. rubella, although normal immunoglobulin-vf can prevent or modify the clinical disease in susceptible rubella contacts if given within 72 hours of exposure, it does not prevent viraemia in such patients. it should, therefore, not be relied upon to prevent congenital malformations due to rubella if given to susceptible pregnant women during the first trimester. measles (morbilli), normal immunoglobulin-vf is indicated for protection against measles in persons exposed less than one week previously. it is recommended in children under six months of age whose mothers have not had the disease, in children between six months and three years of age who have not been actively immunised and in immunosuppressed contacts of the index case. poliomyelitis, normal immunoglobulin-vf is recommended for susceptible contacts who have not been immunised against poliomyelitis.

Israel - English - Ministry of Health

bexsero

glaxo smith kline (israel) ltd - neisseria meningitides group b strain nz98/254; neisseria meningitidis group b fhbp fusion protein; neisseria meningitidis group b nada protein; neisseria meningitidis group b nhba fusion protein - suspension for injection - neisseria meningitides group b strain nz98/254 25 mcg; neisseria meningitidis group b fhbp fusion protein 50 mcg; neisseria meningitidis group b nada protein 50 mcg; neisseria meningitidis group b nhba fusion protein 50 mcg - meningococcus b, outer membrane vesicle vaccine - bexsero is indicated for active immunization of individuals from 2 months of age and older against invasive meningococcal disease caused by neisseria meningitidis group b.

Israel - English - Ministry of Health

lidocaine b.braun 2%

lapidot medical import and marketing ltd - lidocaine hydrochloride monohydrate - solution for injection - lidocaine hydrochloride monohydrate 20 mg/ml - lidocaine - local and regional anaesthesia.severe symptomatic ventricular tachycardia or tachy-arrhythmia, if assessed to be life-threatening.